Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
Clinical trial NCT07151560 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07151560
- Sponsor
- Renmin Hospital of Wuhan University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-30
- Primary completion
- 2027-08-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.